Meet The Experts
Experts' biographies and publications
Dr. Sebastian StintzingRelevant Publications
Dr. Sebastian Stintzing
Sebastian Stintzing (M.D.), Professor of Medicine, is Head of the Division of Oncology and Haematology, Department of Medicine (CCM), Charité Universitaetsmedizin Berlin. His research focuses on predictive and prognostic biomarkers in the treatment of GI cancer with a special focus on colorectal cancer. From 2012 to 2014, he was a research fellow at the Sharon Carpenter Laboratory at the University of Southern California Norris Comprehensive Cancer Center, Los Angeles, U.S.A. He coordinated the translational part and assisted the clinical study conduct of several studies and earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer. In 2012, he received the prestigious Research Fellowship Award from the German Cancer Aid in Germany and started work at the University of Southern California. Dr. Stintzing is member of national and international cancer associations and speaker of the steering committee of the working group Colorectal Carcinoma of the German AIO.
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer Ther. 2015 Oct;14(10):2374-81. doi:10.1158/1535-7163.MCT-15-0121.
Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) Eur J Cancer. 2015 Sep;51(14):1927-36. doi: 10.1016/j.ejca.2015.06.116.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4.
Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013 Jan 1;132(1):236-45. doi: 10.1002/ijc.27654.
Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Jul;23(7):1693-9. doi:10.1093/annonc/mdr571. Epub 2012 Jan 4.
Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer. 2012 Aug 15;131(4):980-6. doi: 10.1002/ijc.26467. Epub 2011 Nov 17.
Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Giessen C, Moosmann N, Heinemann V. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011 Jul 12;105(2):206-11. doi: 10.1038/bjc.2011.227.
Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.
Ass. Prof. Joleen HubbardRelevant Publications
Ass. Prof. Joleen Hubbard
Dr. Joleen Hubbard is an Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota, U.S., and hematology/oncology training at Mayo Clinic, Rochester, Minnesota, U.S. Dr. Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr. Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. Dr. Hubbard is the chair of the Gastrointestinal Tumor Group Practice at Mayo Clinic Rochester, Minnesota, U.S.
De Gramont A, Hubbard J, Shi Q, Association between disease free survival and overall survival delayed with improved survival after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: Findings from the 20,800 patient ACCENT dataset. Journal of Clinical Oncology 28(3):460-5, 2010
Hubbard J, Alberts S. Treatment of Liver-limited Metastatic Disease. The Cancer Journal 2010: 16(3):235-240
Hubbard J, Grothey A. Antiangiogenesis Agents in Colorectal Cancer. Current Opinion in Oncology, 2010 22(4):374-80
Hubbard J, Grothey A. Strategies for Managing Chemotherapy-induced Sensory Neuropathy. Current Colorectal Cancer Reports. 6(3)126–132, 2010
Hubbard J, Sargent D. Evidence for Cure by Adjuvant Chemotherapy in Colorectal Cancer Review. American Journal of Hematology/Oncology 8(9): 419-424, 2009
Hubbard J, Grothey A, Sargent D. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 5:89-99, 2011
Hubbard J, Grothey A. Reduced Chemotherapy Duration: A Good Idea? Current Colorectal Cancer Reports 7(3): 241-245, 2011
Hubbard J, Thomas D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from Adjuvant Colon Cancer Endpoints dataset. Journal of Clinical Oncology. Journal of Clinical Oncology 30(19): 2334 – 2339, 2012
Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res. 2013 Mar;6(2):47-55.
Hubbard, JM, Grothey, A. Adolescent and Young Adult Colorectal Cancer. JNCCN. 2013 Oct 1;11(10): 1219-25. PMID: 24142823.
Hubbard JM, Grothey A. Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12(2):73-4. Epub 2015 Jan 06.
Dr Juan Manuel O’ConnorRelevant Publications
Dr Juan Manuel O’Connor
Dr. Juan Manuel O'Connor is currently Head of the Department of Gastrointestinal Tumors at Instituto Alexander Fleming, a position he has held since 2015. He is Assistant Professor of Clinical Pharmacology at the School of Medicine of the Instituto Universitario CEMIC, Buenos Aires. He is a founding member of the Argentine Group of Neuroendocrine Tumors (ARGENTUM), created in 2005. Dr. O´Connor is a member of the Argentinian Intergroup of Gastrointestinal Tumors (IATTGI), and also of the recently created Latin American Society for Gastrointestinal Tumors, chaired by Dr. Jorge Gallardo. He has been a member of the Advisory Board of the European Society of Neuroendocrine Tumors, ENETS since 2008, and an active member of ASCO since 2011. He finished his fellowship in Clinical Oncology in 2003, held at the Alexander Fleming Institute, affiliated to the University of Buenos Aires, rating with Cum Laude10/10. Dr. O´Connor has authored over 50 papers and chapters of books about gastrointestinal tumors. He received several international awards for his work in the area of neuroendocrine tumors. He has participated in more than 200 national and international events as a speaker. Dr. O´Connor also served as a consultant to the National Cancer Institute in Argentina, and was involved in the development of the Clinical Practice Guidelines in Metastatic Colorectal Cancer in Argentina, in 2014.
Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Biotherapy and Novel Targeted Agents. Neuroendocrinology 2017; 105(3): 266-280
Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. Neuroendocrinology 2017; 105(3): 281-294
Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology 2017; 105(3): 212-244
Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J et al. ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016; 103(2): 144-52
Niederle B1, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 2016; 103(2): 125-38
Sanchez Loria F, Iseas S, O'Connor J et al. Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina. Dig Liver Dis 2016; 48(11): 1372-1377
Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, Raymond E. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol 2015; 75(6): 1099-1104
Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors Neuroendocrinology 2012; 95(2): 120-134
Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42(3): 220-225
Dr. Samuel J. KlempnerRelevant Publications
Dr. Samuel J. Klempner
Dr. Samuel J. Klempner is a GI medical oncologist at Massachusetts General Hospital/Harvard Medical School with research and clinical focus on gastroesophageal cancers and cancer genomics. Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard, Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. Dr. Klempner is board certified in medical oncology, hematology, and internal medicine. Dr. Klempner’s research interests include the intersection of genomics and immunotherapies, oncogene-driven tumors, acquired resistance, and clinical trials of novel agents. Dr. Klempner is involved in professional societies including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO).
Ali SM, Sanford E, Klempner SJ, Rubinson D, Wang K, Palmer N, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci D, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou I S-H, Miller VA. Prospective comprehensive genomic profiling of advanced gastric carcinoma reveals frequent clinically relevant genomic alterations and new routes to targeted therapies. Oncologist 2015; 20:499-507. PMID 25882375.
Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta 2014; 1846:232-237. PMID 24858418.
Le Rolle A-F, Klempner SJ, Garrett C, Seery T, Sanford E, Balasubramanian S, Ross J, Stephens P, Miller VA, Ali SM, Chiu VK. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015; 6:28929-37. PMID 26078337.
Wang K, Johnson A, Ali SM, Klempner SJ, Tanios BS, Vacirca JL, Depinder K, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveal similarities and differences. Oncologist 2015; 20:1132-1139. PMID 26336083.
Klempner SJ, Bordoni R, Gowen K, Kaplan H, Stephens PJ, Ou SH, Ali SM. Identification of BRAF kinase domain duplications across multiple tumor types and response to RAF-inhibitor therapy. JAMA Oncol 2016; 2:272-274. PMID 26562024
Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, Erlich RL, Frampton GM, Sun JX et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol 2016; 27:1336-41. PMID 27052656.
Klempner SJ, Gershenhorn B, Tran P, Lee TK, et al. BRAFV600E mutations in high grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov 2016; 6:594-600. PMID 27048246
Kim ST, Kim SY, Klempner SJ, Yoon J, Kim N, Ahn S, Bang H, Kim K-M, Park W, Park SH, Park JO, Park YS, Lim HY, Lee SH, Park K, Kang WK, Lee J. Rapamycin-insensitive companion of mTOR (RICTOR) Amplification Defines a Subset of Advanced Gastric Cancer and is Sensitive to AZD2014-mediated mTORC1/2 inhibition. Ann Oncol 2017;28:547-554. PMID 28028034
Weinberg B, Gowen K, Lee TK, Ou SH, Bristow R, Krill L, Almira-Suraez I, Ali SM, Liu S, Klempner SJ. Comprehensive genomic profiling aids in distinguishing metastatic recurrence from second primary cancers. Oncologist 2017; 22:152-157. PMID 28193735
Rankin A, Klempner SJ, Erlich R, et al. Broad detection of alterations predicted to confer lack of benefit from EGFR antibodies or sensitivity to targeted therapy in advanced colorectal cancer. Oncologist 2016; 21:1306-1314. PMID 27682134.
Tran PN, Sarkissian S, Chao J, Klempner SJ. PD-1 as an emerging target in gastric cancer: current evidence. Gastrointest Cancer 2017;7:1-11. PMID 28757801
Kim ST, Klempner SJ, Bang H, Park SH, Park JO, Lim HY, Kang WK, Kim K-M, Lee J. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget 2017; 8:77415-77423. PMID 29100397
Dr Cheng Ean CheeRelevant Publications
Dr Cheng Ean Chee
Dr. Cheng Ean Chee is an Assistant Professor of Medicine at Yong Loo Lin School of Medicine, National University of Singapore, Singapore. She completed medical school at University College London, United Kingdom and Internal Medicine Residency and Hematology-Oncology Fellowship at Mayo Clinic, Rochester, Minnesota, USA. Dr. Chee is a clinician-investigator and medical oncologist in gastrointestinal and hepatobiliary cancers at the National University Cancer Institute, Singapore. She is also involved in phase I drug development and is the principal investigator of several phase I and gastrointestinal cancer trials at her institution. As the Program Director for the NUHS Medical Oncology Senior Residency (Fellowship) Program, she is actively involved in the education of the Medical Oncology trainees and she also chairs the Colorectal Cancer Committee of the Singapore Cancer Society. She is an active member of ASCO and the Asian Colorectal Cancer Oncology Group.
Cheng Ean Chee
Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O’Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell JM. Phase II Study of Dasatinib (BMS-354825) in Patients with Metastatic Adenocarcinoma of the Pancreas. Oncologist 2013; 18(10): 1091-2.
Chee CE, Meropol NJ. Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer. Oncologist 2014; 19(7): 704-11.
Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd, Heit JA. Predictors of Venous Thromboembolism Recurrence and Bleeding Among Active Cancer Patients: A Population-Based Cohort Study. Blood 2014; 123(25): 3972-8.
Chan DY, Syn NL, Yap R, Phua JN, Soh TI, Chee CE, Nga ME, Shabbir A, So JB, Yong WP. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? J Gastrointest Surg 2017; 21(3): 425-433.
Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Value of a Molecular Screening Program to Support Clinical Trial Enrollment in Asian Cancer Patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. Int J Cancer 2018 May 1; 142(9): 1890-1900.
Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 2018 Mar 30. [Epub ahead of print]
Prof. Armin GergerRelevant Publications
Prof. Armin Gerger
Since 2012 Dr. Armin Gerger is professor at the Medial University in Graz, Austria. He works as a clinical oncologist and coordinates the Subcentre for Gastrointestinal Neoplasia at the Comprehensive Cancer Centre, Graz. He leads the Pharmacogenetics Research Unit, at the Division of Clinical Oncology of the Medical University of Graz, and the Area “Cancer” of the Centre for Biomarker Research in Medicine (CBmed). Dr. Gerger’s research focuses on prognostic and predictive genetic biomarkers in gastrointestinal cancer, which he developed further as a research fellow at the Norris Comprehensive Cancer Centre of the University of Southern California. Dr. Gerger’s research activity is mirrored in several papers in high-ranked scientific journals and significant extramural funding.
Smolle MA, Pichler M, Haybaeck J, Gerger A. Genetic markers of recurrence in colorectal cancer. Pharmacogenomics. 2015 Jul;16(11):1-14. doi: 10.2217/pgs.15.83. Epub 2015 Aug 12.
Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. Pharmacogenomics J. 2015 Oct;15(5):391-6. doi: 10.1038/tpj.2015.2. Epub 2015 Feb 10.
Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.
Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014 Mar 27;10(3):e1004271. doi: 10.1371/journal.pgen.1004271. eCollection 2014 Mar.
Pichler M, Ress AL, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW, Kiesslich T, Gerger A, Bauernhofer T, Calin GA, Hoefler G. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients.
Br J Cancer. 2014 Mar 18;110(6):1614-21. doi: 10.1038/bjc.2014.51. Epub 2014 Feb 6.
Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, Winder T, Renner W, Gerger A. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clin Cancer Res. 2014 Mar 15;20(6):1687-97. doi: 10.1158/1078-0432.CCR-13-1517. Epub 2014 Jan 27.
Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014 Jan 21;110(2):435-40. doi: 10.1038/bjc.2013.785. Epub 2013 Dec 19.
Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 1;17(21):6934-43. doi: 10.1158/1078-0432.CCR-11-1180. Epub 2011 Sep 14.
Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26.
Gerger A, LaBonte M, Lenz HJ. Molecular predictors of response to antiangiogenesis therapies. Cancer J. 2011 Mar-Apr;17(2):134-41. doi: 10.1097/PPO.0b013e318212db3c. Review.
Assoc. Prof. Gerald PragerRelevant Publications
Assoc. Prof. Gerald Prager
Dr. Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr. Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee.
The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).
Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W, Zielinski CC, Pabinger I, Ay C, Prager GW. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Thromb Res. 2015 Aug 28.
Unseld M, Breuss JM, Pausz C, Pablik E, Schabbauer G, Zielinski CC, Uhrin P, Prager GW. In vivo Tube Assay: An Optimised Protocol of the Directed in vivo Angiogenesis Assay by Implementing Immunohistochemistry. J Vasc Res. 2015;52(2):116-26. doi:
Chillà A, Bianconi D, Geetha N, Dorda A, Poettler M, Unseld M, Sykoutri D, Redlich K, Zielinski CC, Prager GW. Effects of cilengitide in osteoclast maturation and behavior. Exp Cell Res. 2015 Sep 10;337(1):68-75.
Unseld M, Chilla A, Pausz C, Mawas R, Breuss J, Zielinski C, Schabbauer G, Prager GW. PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis. Thromb Haemost. 2015 Aug;114(2):379-89.
Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014 Aug;105(8):996-1001.
Dr. Erika Martinelli, MD, PhDRelevant Publications
Dr. Erika Martinelli, MD, PhD
Dr. Erika Martinelli is an oncologist at the University of Campania "Luigi Vanvitelli" of Naples in Italy. She was awarded her medical degree in 2000, her degree as specialist in Medical Oncology in 2004, and her Ph.D. from the University of Campania "Luigi Vanvitelli" in 2008. Dr. Martinelli’s research focusses on the development of new targeted agents against growth factors in preclinical and early clinical studies, mainly in colorectal cancer, and in particular defining the possible biological markers of intrinsic or acquired resistance to treatments.
Dr. Martinelli is an active member of ESMO. As a member of the ESMO E-Learning and Continuing Medical Education Working Group (ECWG), she is involved in the ESMO E-Learning programme and manages the assessment of courses, symposia, congresses, conferences, and other educational activities, ensuring the high ESMO standards of value and quality. She is also in charge of the assignment of educational hours (ESMO CME points) to proposed activities. Dr. Martinelli is a member of the ESMO Women for Oncology Task Force and was a long-standing member of the ESMO Young Oncologists Committee until the start of 2016.
Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro Ar, Rachiglio M, Lambiase M, Latiano Tp, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; Capri-Goim Investigators; Capri-Goim Investigators. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX ANN ONCOL. 2016 Jun;27(6):1055-61
Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F. AXL is an ocnotarget in human colorectal cancer. ONCOTARGET. 2015
Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. BRITISH JOURNAL CANCER, 2015 Jun 9;112(12):1874-81
Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F. Maintenance treatment with cetuximab and BAY86-9766 increase antitumor efficacy of irinotecan plus cetuximab in human colorectal cancer xenograft models. CLINICAL CANCER RESEARCH, 2015 May 27
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; on the behalf of the CAPRI-GOIM investigators. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. ANN ONCOL. 2015 Apr 7
Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. CLIN CANCER RES. 2014 Jul 15;20(14):3775-86
Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRIGOIM trial. Ann Oncol. 2014 Sep;25 (9):1756-61
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.CLINICAL CANCER RESEARCH. 2013 Dec;19 (24):6751-65
Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. INTERNATIONAL JUORNAL CANCER, 2013, 133: 2089-2101
Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, Dilea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH. Using Pharmacokinetic and Pharmacodynamic Data in Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clin Cancer Res. 2012 Nov 15;18(22):6364-72
Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clinical Cancer Research, 2010, 16:4990-5001
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clinical Cancer Research, 2010,16:4876-83
Tabernero J,Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Vega-Villegas ME, Scheid S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J,Ciardiello F. Pharmacogenomic and pharmacoproteomic studies of Cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. Journal of Clinical Oncology, 2010, 28:1181-9
Tabernero J,Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Rosello S, Liebscher S, Kisker O,Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Annals of Oncology 2009, Nov; 25: 1-9
Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C, Ciardiello F. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C beta inhibitor, in non-small cell lung cancer cells. MolECULAR Cancer TherApeuticS 2008 Jun;7(6):1698-707
>Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Dose and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. JOURNAL OF ClinICAL OncolOGY 2008 Apr 1;26(10):1603-10
Ass. Prof. Cristina NadalRelevant Publications
Ass. Prof. Cristina Nadal
Dr. Cristina Nadal is director of the Global Health Area of the Catalan Healthcare System in Barcelona and an Associate Professor at the University of Barcelona. From 1998 till 2016 she was a colorectal cancer-GI Medical Oncologist at the Hospital Clinic of Barcelona. In addition, she is a member of the Colorectal Cancer Multidisciplinary Board at the Hospital Clinic of Barcelona and an Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Research Member and Representative for the Oncology and Haematology Committee at the IDIBAPS Research Institute.
Urosevic J, Garcia-Albéniz X, Planet E, Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR, Gomis RR. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nature Cell Biology. 2014 Jul;16(7):685-94
Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XHF, Byrom D, Riera A, Rossell D, Mangues R, Massague J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-beta-driven programme in stromal cells for metastasis initiation. Cancer Cell. 2012 Volume: 22 Issue: 5 Pages: 571-584
Arnal-Estapé A, Tarragona M, Morales M, Guiu M, Nadal C, Massagué J, Gomis RR. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms. Cancer Research. 2010 Dec 1;70(23):9927-36.
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J. Genes that mediate breast cancer metastasis to the brain. Nature. 2009 Jun 18;459(7249):1005-9.
Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008 Apr 4;133(1):66-77.
Nadal C, Maurel J, Gascon P. Is there a genetic signature for liver metastasis in colorectal cancer? World J Gastroenterol. 2007; Nov 28;13(44):5832-44. Review.
Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007 May 8; (121):1066-1071
Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova- Todorova K, Massagué J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007 Apr 12;446(7137):765-70.
Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massagué J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006 Sep;10(3):203-14.
Nadal C, Maurel J, Gallego R, Castells A, Longaron R, Mármol M, Sanz S, Molina R, Martin-Richart M, Gascón P. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res. 2005 Jul 1;11(13):4770-4.
Dr. Loredana Vecchione MD, Ph.DRelevant Publications
Dr. Loredana Vecchione MD, Ph.D
Dr. Loredana Vecchione was awarded her medical degree in 2004, her degree as specialist in Medical Oncology in 2008 and her Ph.D from the Second University of Naples in 2012. She performed the last two years of her Ph.D program in Leuven, in Professor Tejpar's group. After achieving the ESMO fellowship for Translational Research in 2012, she joined Professor Bernards' group at the Netherlands Cancer Institute where she has been focusing on identifying vulnerabilities of BRAF-like CC. She recently joined the group of Prof Keilholz at the Comprehensive Cancer Center at the Charite in Berlin where she is investigating mechanisms of resistance to conventional treatments in BRAF-like CC and the role of certain genes in some of the CRC subtypes. Dr. Vecchione is an active member of ESMO. She is involved in the assignment of educational hours (ESMO CME points) to proposed activities. She has been Section Editor of Current Colorectal Cancer Reports since 2014 and Section Editor of Current Oncology Reports since 2015.
Vecchione L, Gambino V, Raaijmakers J, Schlicker A et al A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility Cell 2016; 165(2):317-30
Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features Ann Oncol 2014; 25(10):1995-2001
Geva R, Vecchione L, Kalogeras KT et al FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study Gut 2015; 64(6):921-8
Vecchione L Optimization of anti-EGFR treatment of advanced colorectal cancer Curr Colorectal Cancer Rep 2014; 10:263-271
De Vriendt V, De Roock W, Di Narzo AF, Tian S, Biesmans B, Jacobs B, Budinska E, Sagaert X, Rossi S, D'Ario G, Delorenzi M, Simon I, Vecchione L, Tejpar S DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype Biomarkers 2013; 18(6):516-24
Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells Int J Cancer 2013; 133(9):2089-101
Coffee E, Roper J, Sinnamon M, Faber A, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein B, Bronson R, Tejpar S, Xavier R, Engelman J, Martin E Hung K. Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAFV600E Colorectal Cancer Clin Cancer Res 2013; 15;19(10):10.1158/1078-0432.CCR-12-2556
Geva R, Vecchione L, Tejpar S, Piessevaux H, Van Cutsem E, Prenen H Bevacizumab plus chemotherapy as savage treatment in chemorefractory patients with metastatic colorectal cancer OncoTargets and Therapy 2013; 6:53–58
Troiani T, Vecchione L, Martinelli E et al. Intrinsic resistance to selumetinib, a selective MEK1/2 inhibitor, by CAMP-Dependent Protein Kinase Activation in Human Cancer Cells Br J Cancer 2012; 8;106(10):1648-59
Vecchione L, Saridaki Z, Tejpar S. Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer Curr Colorectal Cancer Rep 2012; 8:42-50
Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol 2011; 15: 9(2):87-97
Dr. Jian LiRelevant Publications
Dr. Jian Li
Prof. Jian Li is Vice Director in the GI Department of Oncology at Peking University Cancer Hospital in China. He received his medical training at Shanghai Medical University and Peking University. He was a visiting scholar at the University of Pittsburgh, USA, throughout 2014. Prof. Li’s special interests are palliative chemotherapy and target therapy of metastatic colorectal cancer, comprehensive treatment of metastatic colorectal cancer, target therapy of gastrointestinal stromal tumor and diagnosis and therapy of digestive endoscope.
Li J, Jin M, Shen L Clinical application of sandostatin in the management of malignant bowel obstruction. Chinese J Gastrointest Surg 2007 Sep;10(5): 479-481.
Li J, Shen L. The efficacy and safety of TS-1 in advanced gastric cancer. Chinese Clin Oncol 2007(9).
Li J, Xu J, Li J, Zhang X, Bai Y, Chu Y, Liu D, Jin M, Shen L. Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer. Chinese J Oncol 2008 Mar;30(3):225-7.
Li J, Shen L. Expression and clinicopathological significance of VEGF-C, -D and VEGFR-3 in gastric carcinoma. Chinese J Cancer Prevention Treatment 2008 Apr; 15(7): 514-517.
Li J, Wu A, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37(2011): 319-324.
Li J, Gong J, Shen L. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor. World J Gastroenterol 2012; 18(7): 698-703.
Li J, Gao J, Hong J, Shen L. The efficacy and safety of sunitinib in Chinese patients with imatinib-resistant/intolerant gastrointestinal stromal tumors. Future Oncol 2012; 8(5): 617–624.
Cao G, Li J (co-first), Shen L, Zhu X. Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases. World J Gastroenterol 2012 November 14; 18(42): 6134-6140.
CSCO Gastrointestinal Stromal Tumor Experts Committee. Consensus of Chinese Gastrointestinal Stromal Tumors Therapists (2011 version). Chinese Clinical Oncology, 2011.
Li J, Dang Y, Gao J, Shen L. Prolonging imatinib adjuvant therapy duration to treat gastrointestinal stromal tumor with intermediate or high risk. Chinese J Gastrointest Surg 2013 Mar.
Li J. The targeted therapy of gastrointestinal stromal tumor. Chinese J Digest Surg 2013 Apr.
Li J, Lu M, Li J, Zhang X, Li Y, Zhan X, Shen L. The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases. Hepatogastroenterology .2013 May;60(123):628-32.
Li J, Dang Y, Gao J, Li Y, Zou J, Shen L. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Med Oncol 2015 Apr;32(4):111.
Gao J, Li J (Co-First), Li Y, Li Z，Gong J，Wu J，Liu N，Dong B，Qi C，Shen L. Intratumoral KIT mutational heterogeneity and recurrent KIT/PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget 2016 May 24; 7(21): 30241–30249.
Li J, Cao H,Shen L, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res 2017;29(4):281-293
Liu D, Li J( Co-First), Shen L, et al. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer 2017; 17: 437
Wang ZH, Li J (Co-First), Shen L, et al. Survival Benefit of Palliative Local Treatments and the Efficacy of Different Pharmacotherapies in Colorectal Cancer with Lung Metastasis: Results From a Large Retrospective Study. Clin Colorect Cancer 2017 2017 Dec 13. pii: S1533-0028(17)30453-X. doi: 10.1016/j.clcc.2017.12.005. [Epub ahead of print]
Li J. Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China. Comparative Effectiveness Research 2017:7 1–9
Ass. Prof. Efrat DotanRelevant Publications
Ass. Prof. Efrat Dotan
Ass. Prof. Efrat Dotan is an Assistant Professor of Medical Oncology at Fox Chase Cancer Center, in Philadelphia. She graduated from the Technion Institute of Technology Medical School in Israel and moved to the US to pursue her specialized training. She completed her residency at Lenox Hill Hospital in New York, and her hematology/oncology fellowship at Fox Chase Cancer Center. Ass. Prof. Dotan specializes in the management of patients with gastrointestinal malignancies, specifically pancreatic cancer. Her research interest is in development of new treatment options for patients with gastrointestinal cancers. She is the PI for multiple clinical trials in this arena. Ass. Prof. Dotan is a member of the Gastrointestinal Malignancies Committee of the Eastern Cooperative Oncology Group (ECOG) and serves as the PI for multiple studies. She also serves as a member of the Pancreatic Cancer Guideline Panel for the National Comprehensive Cancer Network (NCCN). Dr. Dotan’s other interest is in the management of older patients with cancer, and tools to improve the care of this patient population. She has led multiple research projects evaluating the care of older patients with gastrointestinal malignancies. She is a senior member of the Cancer and Aging Research Group, and the chair of the Older Adult Oncology Guidelines for NCCN.
Dotan E, Cohen SJ, Starodub AN, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients with Refractory or Relapsing Metastatic Colon Cancer. J Clin Oncol 2017; 35(29): 3338-3346. PMID: 28817371
Dotan E. Advancing Treatment Approach to the Older Cancer Patient through Clinical Trials Participation. (Book Chapter). Surg Oncol Clin N Am 2017;26(4):719-728. PMID: 28923227
Dotan E. Adjusting our Current Practice for the Older Patient with Cancer. Editorial. J Oncol Pract 2017;13(2):103-104. PMID:28972828
Vijayvergia N, LI T, Wong YN, Hall MJ, Cohen SJ, Dotan E. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer 2016;122(20): 3191-3198. PMID: 27379436
Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Halbherr T, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients with Metastatic Pancreatic Adenocarcinoma. Pancreas 2016;45(8):1131-5. PMID: 26967453
Vijayvergia N, Dotan E, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience. J Geriatr Oncol. 2015 Nov;6(6):454-61. PMID: 26296909
Dotan E, Tianyu Li, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. J Oncol Pract September 2014;10(5):308-14. PMCID: PMC4161728.
McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol August 2014;32:2570-2580. PMID:25071118
Dotan E, Neal J. Meropol, et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer December 2012,43(4), 562-569. PMCID: PMC3400721.
Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Relationship of increased Aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 2012 Feb 14;106(4):748-55. PMID:22240781
Dr Victor Hugo Fonseca de JesusRelevant Publications
Dr Victor Hugo Fonseca de Jesus
Dr. Victor Hugo Fonseca de Jesus is a Medical Oncologist at A.C. Camargo Cancer Center, Sao Paulo, Brazil. He graduated from medical school in 2008 and completed his training as a Medical Oncologist in 2014. His main area of interest concerns the management of patients with gastrointestinal malignancies and he is currently involved in the field of clinical research in gastrointestinal oncology. In 2017, Dr. Fonseca received the board certification from the Brazilian Society of Medical Oncology. He is currently undergoing Master of Science (MSc) training in Oncology and he is an active member of the American Society of Clinical Oncology (ASCO) and of the European Society of Medical Oncology (ESMO).
de Jesus VHF, Ribeiro TN, Chinen LTD, Alves V, Curado MP, Fanelli MF. Epidemiological Profile and Treatment Outcomes in Young Adults (19–29 years of Age) Treated for Cancer in a Tertiary Hospital in São Paulo, Brazil. J Adolesc Young Adult Oncol 2017 Jun;6(2):333-40.
Fava BEC, da Costa Jr WL, Medeiros MLL, Sonagli M, Ribeiro HSC, Diniz AL, Godoy AL, de Farias IC, de Jesus VHF, Begnami MDFS, Coimbra FJF. Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center. World J Surg Oncol 2018 Mar 22;16(1):62.
de Jesus VHF, da Costa Jr WL, Marques TMDM, Diniz AL, Ribeiro HSC, Godoy AL, de Farias IC, Coimbra FJF. Role of staging laparoscopy in the management of Pancreatic Duct Carcinoma (PDAC): Single-center experience from a tertiary hospital in Brazil. J Surg Oncol 2018 Apr;117(5):819-828.
de Jesus VHF, Camandaroba MPG, Donadio MDS, Cabral A, Muniz TP, Leite LM, Sant’Anna LF. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol 2018;ahead of print.
Paiva Jr TF, de Jesus VHF, Marques RA, da Costa AABA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VCC. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015 Sep 22;15:643.
Marques MC, Ribeiro HSC, Costa Jr WL, de Jesus VHF, de Macedo MP, Diniz AL, Godoy AL, Farias IC, Aguiar Jr. S, Riechelmann RSP, Begnami MDFS, Coimbra FJF. Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)? J Surg Oncol 2018 Apr;117(5):858-63.
Ass. Prof. Yu SunakawaRelevant Publications
Ass. Prof. Yu Sunakawa
Dr. Yu Sunakawa is a medical oncologist at St. Marianna University, Japan and previously worked as an instructor at Showa University Northern Yokohama Hospital in Yokohama, Japan. He also completed postdoctoral research fellowship training at University of Southern California/Norris Comprehensive Cancer Center in United States. In 2011, Dr. Sunakawa received the board certification of the Japanese Society of Medical Oncology. Dr. Sunakawa’s research interests are the identification and determination of molecular markers in cancerous tissues or blood that could predict cancer risk and clinical outcome in gastrointestinal cancer. He is also focusing on research regarding tumour immunity and received a Merit Award from the American Society of Clinical Oncology in 2014, for the research of genetic variations in immune checkpoint-related genes.
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Ann Oncol. 2015 Sep 28. pii: mdv474.
Sunakawa Y, Lenz HJ. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options Oncol. 2015 Apr;16(4):17. doi: 10.1007/s11864-015-0331-y.
Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol. 2015 Feb;26(2):332-9. doi: 10.1093/annonc/mdu542. Epub 2014 Nov 18.
Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, Mitsunaga S, Hashizume K, Ito Y, Sasaki Y. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2014 Feb;32(1):104-12. doi: 10.1007/s10637-013-9953-8. Epub 2013 Apr 4.
Prof. Hans PrenenRelevant Publications
Prof. Hans Prenen
Dr. Hans Prenen obtained his medical degree in 2001 from the Catholic University Leuven (K.U. Leuven, Belgium). In 2006, he gained his PhD from the molecular oncology program at K.U Leuven. Since 2009, he has been working in the division of gastroenterology at the University of Leuven Hospital, in digestive oncology. He is currently an Associate Professor of Medicine at the K.U. Leuven as well as a Senior Clinical Investigator of the Belgian Foundation against Cancer, where his research initially focused in understanding how certain mutations in cancer cells dictate resistance to targeted agents. Recently, he became attracted by the relevance of inflammatory cells as diagnostic, prognostic and predictive markers. Dr. Prenen is a member of many scientific organizations, including the European Society of Medical Oncology, the Belgian Society of Medical Oncology, the Belgian Group of Digestive Oncology, and the International Society for Diseases of the Esophagus and the European Organisation for the Research and Treatment of Cancer.
Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, Mazzone M. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015 Jun 18;522(7556):349-53
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19
Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, D'Hoore A, Iserentant H, Hendlisz A, Mazzone M. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.Gut. 2015 Mar 26. pii: gutjnl-2014-308988
Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1;30(28):3499-506
Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009 May 1;15(9):3184-8
Prof. Tanios Bekaii-SaabRelevant Publications
Prof. Tanios Bekaii-Saab
Dr. Tanios Bekaii-Saab, M.D., is Medical Oncologist at Mayo Clinic. From 2002 Dr. Bekaii-Saab joined the faculty at The Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute, where he is a tenured Professor of Medicine and Pharmacy, and section chief for the gastrointestinal cancer program. He is the chairman of the disease specific research group for the comprehensive cancer center. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts. Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on gastrointestinal malignancies, molecular targeted and immune therapies. Dr. Bekaii-Saab is actively involved in professional societies including the American Society of Clinical Oncology, American Association for Cancer Research, American Society for Clinical Pharmacology and Therapeutics, and the Alliance cooperative group.
Dr. Jenny SeligmannRelevant Publications
Dr. Jenny Seligmann
Dr. Jenny Seligmann gained her MBChB and BMedSci at the University of Aberdeen in 2005 then gained her PhD in 2015 from the University of Leeds on Biomarkers of Prognosis and Prediction of Response in Colorectal Cancer. She was appointed a Cancer Research UK Clinical Trials Fellow in 2015, then a University Academic Fellow and Consultant in Medical Oncology in Leeds in 2017. Her research interests are in clinical trials and biomarkers of prediction of response in colorectal cancer. She is involved in several ongoing clinical trials, including the FOCUS-4 trial and has an ongoing lab-based programme of research. She has been involved in several national and international committees, including the UK Colorectal Clinical Studies Group and is currently the EORTC GI Group Young Investigator. She has received several awards including an ASCO Merit Award in 2013.
Seligmann J, Hatch A, Richman S et al. Association of tumor HER3 messenger RNA expression with panitumumab efficacy in advanced colorectal cancer. JAMA Oncol 2017; Doi;10.1001/jamaoncol.2017.3168
Seligmann J, Seymour M. Use of gene expression profiles to distinguish molecular sub-types in colorectal cancer- progression towards primetime. J Natl Cancer Inst 2017; 109(7): djx019
Seligmann J, Fisher D, Richman S et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Annals of Oncol 2017; 28(3): 562-568
Seligmann J, Elliott F, Richman S, et al. Combined epiregulin and amphiregulin expression as a biomarker of prognosis and panitumumab benefit in advanced colorectal cancer. JAMA Oncol 2016; 2(5):633-52
Young A, Marshall E, Seligmann J et al. Responding to acute care needs of patients with cancer: recent trends across continents. Oncologist 2016; 21(3): 301-7
Mefshar M., Hamilton P, Seligmann J et al. Can d-dimer measurement reduce the frequency of radiological assessment in patients receiving palliative imatinib for gastrointestinal stromal tumor (GIST)? Cancer Invest 2015; 33(8): 347-53
Seymour M, Brown S, Seligmann J et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-759
Dr. Thomas WinderRelevant Publications
Dr. Thomas Winder
Dr. Thomas Winder, M.D. Ph.D. graduated in 2005 from the Medical University of Innsbruck. He became Dr. scient.med. at the Private University of Liechtenstein in 2008, with his thesis: “Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal Cancer”. In 2010, he completed his Ph.D. studies at the Private University Liechtenstein in co-operation with the University of Southern California, Norris Comprehensive Cancer Center with his thesis: “Predictive and prognostic molecular markers in gastrointestinal malignancies”.
His main research area is the predictive and prognostic molecular markers in gastrointestinal malignancies. He presently holds professional positions with many different society memberships and is an active reviewer for diverse journals.
Bohanes P, Rankin C, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martenson JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg KD, Makar KW, Zhang W, Benedetti JK, Lenz HJ. Pharmacogenetic analysis of INT 0144 trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation. Clin Cancer Res. 2015 Apr 1;21(7):1583-90.
Purohit B, Winder T, Maggio EM, Kollias SS. Aggressive primary olfactory neuroblastoma of the sphenoclival region: A case report and literature review. Laryngoscope. 2014 Sep 12. doi: 10.1002/lary.24925. [Epub ahead of print]
Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol. 2014 May 28;20(20):6102-6112.
Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Lang AH. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. Eur J Cancer. 2014 Jun 5. pii: S0959-8049(14)00657-1. doi: 10.1016/j.ejca.2014.05.007. [Epub ahead of print]. Impact Factor 5.061 (2012 Journal Citation Reports).
Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, Winder T, Renner W, Gerger A. A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clin Cancer Res. 2014 Jan 27. [Epub ahead of print]
Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. Plastin polymorphisms predict gender and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2013 Oct 29. [Epub ahead of print]
Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T, Langsenlehner U, Samonigg H, Renner W, Gerger A. A common and Bibliography Thomas Winder, MD PhD October 2015 2 functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog. 2013 Nov;52 Suppl 1:96-102. doi: 10.1002/mc.22028. Epub 2013 Apr 26.
Winder T, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics J. 2013 Mar 5. doi: 10.1038/tpj.2013.8. [Epub ahead of print]
Szkandera J*, Winder T*, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, Samonigg H, Renner W, Gerger A, Absenger G. A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol. 2013 Apr 3. [Epub ahead of print]
Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T, Langsenlehner U, Samonigg H, Renner W, Gerger A. A Common and Functional Gene Variant in the Vascular Endothelial Growth Factor A Predicts Clinical Outcome in Early-Stage Breast Cancer. Mol Carcinog. 2013 Apr 26. doi: 10.1002/mc.22028. [Epub ahead of print]
Muendlein A, Lang AH, Geller-Rhomberg S, Winder T, Gasser K, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Hubalek M. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. J Cancer Res Clin Oncol. 2013 Mar;139(3):491-8.
Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. Influence of Sex on the Survival of Patients With Esophageal Cancer. J Clin Oncol. 2012 Jun 20;30(18):2265-72. Epub 2012 May 14.
Prof. David TougeronRelevant Publications
Prof. David Tougeron
Dr. David Tougeron is a professor of gastroenterology at Poitiers University Hospital, France. His clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer. Dr. Tougeron has participated in more than 40 clinical trials in digestive oncology and has co-authored more than 50 articles, editorials and book chapters. After a Ph.D. in immune response in colorectal cancer, Dr. Tougeron completed a postdoctoral position at the Mayo Clinic, U.S., in colorectal cancer chemosensitivity. His research is currently focussing on colorectal cancer, particularly colorectal cancer with microsatellite instability and predictive biomarkers of response to targeted therapies. He presently holds professional positions in different organisations, notably the Fédération Francophone de Cancérologie Digestive (FFCD).
Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboue R, Laurent M, Berthet P, Mauillon J, Di Fiore F, Sabourin JC, Michel P, Tosi M, Frebourg T, Latouche JB. Tumor infiltrating lymphocytes in MSI colorectal cancers are correlated to number and spectrum of frameshift mutations. Mod Pathol. 2009;22:1186-95.
Tougeron D, Roullet B, Paillot B, Fruge F, Hamidou H, Tourani JM, Bensadoun RJ, Michel P, Silvain C. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: a bicentric analysis. Dig Liver Dis. 2012;44:350-4.
Tougeron D, Maby P, Elie N, Fauquembergue E, Le Pessot F, Cornic M, Sabourin JC, Michel P, Frébourg T, Latouche JB. Regulatory T lymphocyte infiltrate density is associated with lower invasiveness in microsatellite-unstable colorectal cancers. PlosOne. 2013;8:e61001.
Tougeron D, Lecomte T, Pagès JC, Collin C, Villalva C, Ferru A, Tourani JM, Silvain C, Levillain P, Karayan L. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24:1267-73
Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2013;72:397-403.
Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA. For the Alliance for Clinical Trials in Oncology. KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clin Cancer Res. 2014;20:3033-43.
Tougeron D*, Park JM*, Huang S, Okamoto S, Sinicrope FA. * Co-auteurs. Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells. PlosOne. 2014;9:e100819.
Maby P, Tougeron D, Hamieh M, Kora H, Mlecnik B, Bindea G, Angell H, Fredriksen T, Elie N, Fauquembergue E, Drouet A, Leprince J, Benichou J, Mauillon J, Le Pessot F, Sesboüe R, Frébourg T, Galon J, Latouche JB. Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75:3446-55
Tougeron D, Sickersen G, Mouillet G, Zaanan A, Trouilloud I, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Lecomte T. Prognostic factors in colorectal cancers with microsatellite instability: An AGEO multicenter study. Eur J Cancer. 2015;51:925-34.
Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: Back to the Future. Clin Cancer Res. 2014;20:1087-94.
Guillebon E, Roussille P, Frouin E, Tougeron D. World J. Anti PD-1/anti PD-L1 in digestive cancers Gastrointest Oncol 2015;7:95-101.
Dr. Dominik ModestRelevant Publications
Dr. Dominik Modest
Dr. Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, he is a physician at the Ludwig-Maximilians-University of Munich, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Dr. Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy. Dr. Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.
Dr. Dominik Paul Modest
Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer. 2016 Feb 1;138(3):739-46.
Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. J Clin Oncol. 2015 Nov 10;33(32):3718-26
Camaj P, Primo S, Wang Y, Heinemann V, Zhao Y, Laubender RP, Stintzing S, Giessen-Jung C, Jung A, Gamba S, Bruns CJ, Modest DP. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. Future Oncol. 2015;11(13):1919-29
Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anticancer Drugs. 2015 Apr;26(4):371-8
von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014 May 10
Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs. 2014 Feb;25(2):212-8
Modest DP, Camaj P, Heinemann V, Schwarz B, Jung A, Laubender RP, Gamba S, Haertl C, Stintzing S, Primo S, Bruns CJ. KRAS-allel specific activity of sunitinib in an isogenic disease model of colorectal cancer. J Cancer Res Clin Oncol 2013 Mar 2
Modest DP, Laubender RP, Stintzing S, Giessen C, Schulz C, Haas M, Mansmann U, Heinemann V. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial. Acta Oncol 2012 Dec 18.
Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, Kirchner T, Heinemann V, Zielinski CC. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology. 2012;83(5):241-7
Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. Anticancer Drugs. 2012 Jul;23(6):666-73.
Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer. 2012 Aug 15;131(4):980-6.
Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, Stemmler HJ, Kirchner T, Heinemann V. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs. 2011 Oct;22(9):913-8.
Dr. Guillem ArgilésRelevant Publications
Dr. Guillem Argilés
Dr. Guillem Argilés obtained his medical degree at the Vall d’Hebron University Hospital in Barcelona, Spain. He later obtained his M.D., supervised by José Baselga M.D., in 2006 at the same institute. In 2010, he joined the Gastrointestinal Malignancies Division led by Josep Tabernero M.D., Ph.D.
Dr. Argilés currently works in the Gastrointestinal Malignancies and Developmental Therapeutics Divisions of the same institute, where his research is focused on chemorefractory colorectal cancer, personalized medicine, as well as the molecular biology of colorectal cancer.
Elez E, Argilés G, Tabernero J.First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. Curr Treat Options Oncol. 2015 Nov;16(11):52. doi: 10.1007/s11864-015-0369-x
Celina GG, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jassen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cáncer. Clin Cancer Res. 2015 Aug 13. Pii: clincanres.3091.2015 [Epub ahead of print]
Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cáncer. Clin Cancer Res. 2015 Jul 29. Pii:clincanres.3081.2014 [Epub ahead of print]
Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A Gupta S. Results of a phase 1 trial combining ridaferolimus and MK-0752 in patients with advanced solid tumors. Eur J Cancer. 2015 Sep;51(14):1865-73.
Gupta S, Argilés G, Munster PN, Hallebecque A, Dajani O, Cheng J, Wang R, Swift A, Tosolini A, Piha Paul SA. A phase 1 Trial of Combined Ridaforolimus and MK-2206 in Patients With Advanced Malignancies. Clin Cancer Res. 2015 Jul 17. Pii: clincanres.0180.2015 [Epub ahead of print]
Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BBJ, van der Post B, Argilés G, Skartved N JØ, Hansen UH, Hald R, Pedersen M, Kragh M, Horak ID, Braun S, van Cutsem E, Tolcher TW, Tabernero J. Safety and Activity of the First-in-class Sym004 Anti-EGFR Antibody Mixture in Patients with Advanced Cancer. Cancr Discov. 2015 jun;5(6):598-609.
Argilés G, Saunders MP, Ribera F, Sobrero A, Benson A, Guillen-Ponce C, Cascinu S, Van Cutsem E, McPherson IA, Strumberg D, Köhne CH, Zlacberg J, Wagner A, Garosi VL, Grunert J, Tabernero J, Ciardello F. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. Eur J Can. 2015 Mar 24 pii: S0959-8049 (15)00213-0
Sastre J, Argilés G, Benavides M, Feliu J, García-Alfonso P, García-Carboner R, Grávalos C, Guillén-Ponce C, Martínez-Villacampa M, Pericay C. Clinical management of Regorafenib in the treatment of patients with advanced colorectal cáncer. Clin Trans Oncol. 2014 Sep 16. (Epub ahead printed).
Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Plamer HG. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cell. Clin Cancer Res. 2013 Dec 15;19(24):6787-801
Argilés G, Rodon J, Tabernero J, Depicting the evolving scenario of translational-guided drug development. Clin Transl Oncol. 2012 Dec;14(12):881-2
Argilés G, Dienstmann R,Elez E, Tabernero J. Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncol. 2012 Apr;8(4):373-89.
Dr. Chiara CremoliniRelevant Publications
Dr. Chiara Cremolini
Dr. Chiara Cremolini is a Medical Oncologist at Santa Chiara University Hospital in Pisa, Italy. Chiara completed her M.D. Degree in 2008, and gained an M.Sc. in Clinical Trials in 2011, and the Specialty in Medical Oncology in 2014 at the University of Pisa. She is mainly committed to the clinical management of patients affected by gastrointestinal malignancies and is involved in clinical and translational research projects in the field of colorectal oncology. She actively contributes to clinical trials by the cooperative Gruppo Oncologico Nord Ovest (GONO) group and is interested in the identification of molecular predictors of benefit from systemic treatments. Chiara is co-author of about 60 peer-reviewed papers and received merit awards at the following meetings: American Society of Clinical Oncology (ASCO) 2010, 2012−2015; European Society for Medical Oncology (ESMO) 2011 and 2014; European CanCer Organisation (ECCO) 2013.
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A: PTEN expression and KRAS mutations on primaries and metastases in the prediction of benefit from cetuximab plus irinotecan for metastatic colorectal cancer patients. Journal of Clinical Oncology 2009 Jun 1;27(16):2622-9.
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 Jul 14; 101(4):715-21
Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010 Sep;11(9):845-52.
Loupakis F, Cremolini C, Salvatore L et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014 Jan;50(1):57-63.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18
Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Early Tumor Shrinkage and Depth of Response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015 Feb 23. pii: mdv112. [Epub ahead of print]
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jun 1. doi: 10.1038/nm.3870. [Epub ahead of print]
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015 Jul 7. pii: mdv290. [Epub ahead of print]
Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC-a review and evidence-based algorithm. Nat Rev Clin Oncol. 2015 Jul 28.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Aug 28. pii: S1470-2045(15)00122-9
Dr. Fotios LoupakisRelevant Publications
Dr. Fotios Loupakis
Dr. Loupakis gained his M.D. Degree at the University of Pisa, Italy in 2003, followed by Master of Science in Clinical Trials (M.S.) in 2005, the Specialty in Oncology from the Department of Oncology of the same University in 2007, and a Research Doctorate in Health Biotechnologies (Ph.D.) in 2011. From 2016 Dr. Loupakis has worked as a Clinical Trial Coordinating Physician in the GI Cancers Team at the Istituto Oncologico Veneto in Padua, Italy.
Since 2009 he has worked as a Medical Oncologist at the University Hospital Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, and since 2010, he has been an Assistant Professor at the Department of Oncology. Since 2012, Dr Loupakis has also been the Coordinator of the Colorectal Cancer Multidisciplinary Team and the Trials Office. From 2011 to 2012 he was a Research Fellow at the University Of Southern California Keck School Of Medicine, Los Angeles, in the United States.
Dr. Loupakis is author and co-author of over 100 scientific publications in peer reviewed journals. He has received International rewards such as the ASCO Merit Award and The Lorini Foundation Merit Award.
The focus of his research field is on clinical and pre-clinical oncology with particular attention given to the transfer of the developments achieved in the field of pharmacology and experimental oncology into translational research.
Renfro LA, Loupakis F, Adams RA, Seymour MT, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2015 Oct 26. PMID: 26503203.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Aug 28. [Epub ahead of print]PMID: 26338525.
Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015 Jul 7. pii: mdv290. [Epub ahead of print] PMID: 26153495.
Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015 Feb 24;107(3). PMID: 25713148
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18. PMID: 25337750
Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2013 Oct 15. PMID: 24138831
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. PMID: 23836314
Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G, Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer. 2013 Jun 25;108(12):2549-56. PMID: 23703247
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009 Aug 18;101(4):715-21. Epub 2009 Jul 14. PMID: 19603018
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009 Jun 1;27(16):2622-9. PMID: 19398573
Dr. Shubham PantRelevant Publications
Dr. Shubham Pant
Dr. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. He previously served as the Director of Clinical Trials for the Section of Hematology-Oncology and Associate Director of the Tobacco Settlement Endowment Trust (TSET) Phase 1 program, for the Stephenson Cancer Center in Oklahoma City. Furthermore Dr. Pant was the Oncology Lead of the Clinical Research Disease Site Group for Gastrointestinal Cancers and Clinical Research Disease Site Group Chair for Hepatocellular Cancers at the same institute. Dr. Pant completed his fellowship from the Ohio State University, where he was elected Chief Fellow. He previously served as an elected member at large to the Board of Directors for Cancer and Leukemia Group B (CALGB), was the Site Principal Investigator for CALGB and was a Member of the Board of Trustees for ACTION. Dr. Pant served on the Board of Oklahoma Society of Clinical Oncology. He is a participant in the ASCO Leadership Development Program, Class of 2015-16. His awards include the Golden Pillar Award for Outstanding Patient Service in 2012 and 2014, America's Top Doctors by Castle Connolly and Oklahoma 40 Under 40 in the Oklahoma Magazine. In 2015, he anchored a health show on CNN-IBN India titled: ‘Let’s Talk Health’.
Pant S, Burris H, Moore K, et all. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase Inhibitor, in patients with advanced solid tumors. Invest New Drugs. 32(1):87-93, 2/2014. PMID: 23525756.
Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 120(12):1780-6, 6/15/2014. PMID: 24633933.
Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann of Oncol 25(7):1416-1421, 7/2014. PMID: 24737778.
Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. e-Pub 7/25/2014. [Epub ahead of print] PMID: 25068471.
Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein P.J., Rolfe L, Saif M.W., LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 14(5):398-402, 9-10/2014. e-Pub 7/2014. PMID: 25278310.
Dr Autumn McReeRelevant Publications
Dr Autumn McRee
Dr. Autumn McRee is an Associate Professor of Medicine specializing in gastrointestinal (GI) medical oncology at The University of North Carolina (UNC). She graduated from the McGovern Medical School at The University of Texas in Houston and completed her Internal Medicine residency at Vanderbilt University. During her hematology/oncology fellowship at UNC, she developed an interest in GI oncology and now as faculty, has established a career dedicated to early drug development and experimental therapeutics with an emphasis in pancreatic and hepatobiliary cancers. Dr. McRee demonstrates the unique combination of clinical trial productivity and correlative science knowledge that has allowed her to seamlessly bridge the gap between scientists and clinicians with a translational research focus in tissue-based research, next generation sequencing and bioinformatics. She oversees the GI clinical trials program at UNC, serving as PI for trials both industry sponsored and investigator initiated. Dr. McRee also is an active member of the Alliance for Clinical Trials in Oncology and co-chairs the Hoosier Cancer Research Network GI Clinical Trials Working Group.
Griffith AS, Hayashi PH, Burke L, McRee AJ. Decreased hepatocellular carcinoma tumor burden with achievement of HCV SVR: unlocking the potential of T-cell mediated immunosurveillance. Journal of Hepatocellular Carcinoma, In Press.
McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM and Dees EC. A phase I trial of the PI3K inhibitor buparlisib in combination with capecitabine in patients with metastatic breast cancer. Clinical Breast Cancer, Epub ahead of print, Oct. 2017 PMID: 29153866
Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary approach to the management of esophageal malignancies. World J Surg 2017; 41(7): 1726-1733. PMID: 28361298
Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot e, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman T, Rhie SK, Bowlby R, Borad MJ, Stuart JM, Sander C, Akbani R, Cherniack AD, Laird PW, Deshpande V, Mounajjed T, Foo WC, Torbenson M, Kleiner DE, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, and Kwong LN. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Reports 2017; 18 (11): 2780-2794. PMID: 28297679
Cleary J, McRee A, Shapiro GI, Tolaney S, O’Neil B, Kearns J, Matthews S, Nering R, MacBeath G, Czibere A, Sharma S and Korn M. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Investigational New Drugs 2017; 35 (1): 68-78. PMID: 27853996
Paul B, O’Neil BH and McRee AJ. Checkpoint inhibition for colorectal cancer: progress and possibilities. Immunotherapy 2016; 8 (6): 693-704. PMID: 27197538
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, and Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer: results from the phase 1b KEYNOTE-012 study. Lancet Oncology 2016; 17 (6): 717-726, PMID: 27157491
McRee AJ, Sanoff HK, Carlson C, Ivanova A, and O’Neil BH. A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational New Drugs 2015; 33 (6): 1225-1231. PMID: 26490655
McRee AJ and O’Neil BH. The role of HIPEC in GI malignancies: controversies and conclusions. Oncology 2015; 29(7) 2015. PMID: 26178341
O’Neil BH, Scott AJ, Aisner DL, Baranda JC, Cohen SJ, Tejani MA, Cohen DJ, Ma WW, Gomes C, Cho JK, Olowokure OO, Coveler AL, Menter AR, Rubin P, Cusnir M, Boles J, Philip P, Radford J, McRee AJ, Berlin J, Rarick M, Nazezmzadeh R, Fehrenbacher L, Bharadqaj J, Bathini V, Marshke R, Chin S, Fanta P, and Messersmith WA. A phase I/II randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015; 26(9): 1923-1929. PMID: 26945010
Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O’Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs 2015; 33 (2): 505-509. PMID: 25613083
Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang D, Snavely A, Rogers AB, Montgomery SA, Rathmell WK, McRee AJ. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer 2015; 5: 61-71, 2015. PMID: 25844041
McRee AJ, Davies JM, Sanoff H, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A and O’Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol 2014; 74 (1): 117-123. PMID: 24819684
McRee AJ, O’Neil BH. Using molecular markers to guide therapy of metastatic colorectal cancer. J Oncopathol 2013; 1(3):21-29, 2013. PMID: 26640695
McRee AJ, Goldberg RM. Optimal management of metastatic colorectal cancer: current status. Drugs 2011; (7):869-84. PMID: 21568364
McRee AJ, Cowherd S, Wang A, Goldberg RM. Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncol 2011; 7(3):409-426. PMID: 21417904
Dr. Andrea Sartore-BianchiRelevant Publications
Dr. Andrea Sartore-Bianchi
Dr. Andrea Sartore-Bianchi is head of Clinical Molecular Oncology at the Department of Hematology & Oncology, Niguarda Cancer Center, Milano, Italy. He completed his medical degree at the University of Pavia in 1999, and undertook specialist training at IRCCS Policlinico San Matteo. After completing his doctoral studies, he conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics in the Department of Medicine at Brown University, Rhode Island, USA.
Dr. Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-II-III clinical trials for gastrointestinal malignancies, and first author of research articles in the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and PLoS One. Currently, he is adjunct Professor for the School of Specialization in Oncology and Pharmacology at the University of Milano. He has been listed among the top 30 authors of primary research papers on cancer.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):738-46. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20
Sartore-Bianchi A, Loupakis F, Argilés G, Prager GW. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol. 2016 Aug;27(8):1456-66. doi: 10.1093/annonc/mdw191. Epub 2016 May 6. Review
Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2015 Nov 12;108(1). pii: djv306. doi: 10.1093/jnci/djv306. Print 2016 Jan.
Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann Oncol. 2016 Jun;27(6):1062-7. doi: 10.1093/annonc/mdw071. Epub 2016 Feb 24
Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer.
Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Nat Med. 2015 Jul;21(7):827.
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014 Nov;4(11):1269-80. doi: 10.1158/2159-8290.CD-14-0462. Epub 2014 Oct 7. Review.
Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A. MolThe TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12
Sartore-Bianchi A, Zeppellini A, Amatu A, Ricotta R, Bencardino K, Siena S. Regorafenib in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014 Mar;14(3):255-65. doi: 10.1586/14737140.2014.894887
Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, CameronJL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A,
Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2
Ricotta R, Sartore-Bianchi A, Verrioli A, Vanzulli A, Siena S. Regorafenib for metastatic colorectal cancer. Lancet. 2013 May 4;381(9877):1537. doi:10.1016/S0140-6736(13)60976-9
Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G,
Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013 Apr 15;19(8):2265-72. doi: 10.1158/1078-0432.CCR-12-3518
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2
Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, Cappuzzo F, Vander Borght S, Martin V, Skokan M, Santoro A, Gambacorta M, Tejpar S, Varella-Garcia M, Siena S. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol. 2012 Mar;65(3):218-23. doi: 10.1136/jclinpath-2011-200353. Epub 2011 Nov 30. Erratum in: J Clin Pathol. 2012 Jul;65(7):674
Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10